5 hours ago
1
Sun Pharma Q4 FY25 Earnings: Sun Pharma, a Mumbai-headquartered pharmaceutical giant, on Thursday reported a consolidated net profit of Rs 2,154 crore for the quarter ended March 31, missing analysts' estimates. The quarterly net profit fell 19 per cent compared with the corresponding period a year ago, according to a regulatory filing.
The drug maker's March-quarter revenue grew 8.1 per cent on a year-on-year basis to Rs 12,959 crore, according to the filing.
According to Zee Business research, Sun Pharma was estimated to register a net profit of Rs 2,795 crore with revenue of Rs 13,350 crore for the final three months of FY25.
Sun Pharma Q4 FY25 Results | How the Mumbai-based pharma firm fared operationally
Sun Pharma's margin improved to 28.68 per cent for the quarter ended March 31, 2025, from 25.32 per cent a year ago.
Margin is a key measure of a company's profitability.
Sun Pharma Q4 Earnings | How the Mumbai-based pharma firm fared operationally
Sun Pharma's margin improved to 28.68 per cent for the quarter ended March 31, 2025, from 25.32 per cent a year ago.
Dividend per share
The pharma firm declared a dividend of Rs 5.5 per share to shareholders—a 550 per cent payout given the face value of Re 1 per equity share.
English (US) ·